The Cooper Companies, Inc. · NASDAQ:COO
The Cooper Companies — Investor Presentation (January 2022)
21 slides from The Cooper Companies's investor presentation, Jan 10, 2022
Slide 1: Investor Presentation
Investor Presentation January 10, 2022 1
Slide 2: Cautionary Statements
Cautionary Statements Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statement
Slide 3: A Leading Medical Device Company
A Leading Medical Device Company Improving lives one person at a time FY21 Revenue $2.92B 12,000+ Business Unit Geography Global Industry-leader in Workforce Vision and Women’s Health 10+ Women's Asia Pacific Health Manufacturing and Distribution Sites Member of the Americas S&P 500 since 100+ 2016
Slide 4: CooperCompanies annual sales growth 2016 to 2021
CooperCompanies 8.2% annual sales growth from 2016 to 2021 $2,923 $2,533 $2,653 $2,431 $1,967 $2,139 FY16 FY17 FY18 FY19 FY20 FY21 Note: Sales $ in millions; Annual sales growth is a five-year CAGR 4
Slide 5: Fiscal 2022 financial guidance
CooperCompanies Fiscal 2022 financial guidance FY22 Guidance* Growth vs. FY21 Total $3,032 - $3,090 6% - 8% cc Sales CooperVision $2,225 - $2,267 6% - 8% cc CooperSurgical $807 - $823 6% - 8% cc EPS Non-GAAP $13.60 - $14.00 9.5% - 12.5% cc Note: Sales $ in millions; cc means constant currency; Non-G
Slide 6: CooperVision
CooperVision A global leader dedicated to helping improve the way people see each day 6
Slide 7: Global Soft Contact Lens Market
Global Soft Contact Lens Market High Barriers to Entry Market by Competitor Market by Category • High capital outlay with highly specialized manufacturing • Technological know-how Other CVI 12% Toric • Stringent FDA and worldwide regulation 25% 24% • Long history of product innovation (SiHy with int
Slide 8: The Growing Myopia Epidemic
The Growing Myopia Epidemic Myopia is expected to affect half the world population by 2050 Worldwide Prevalence of Myopia 4.7 billion 50% Why? Increased Less time screen time outdoors Genetics 2.6 billion 34% Myopia Significant Impact to Impaired 0.9 billion ocular quality of Risks health learning a
Slide 9: Contact Lens Market Drivers
Contact Lens Market Drivers Strong fundamental growth drivers ▪ New fits/trade-up ▪ Shift into 1 Day SiHy lenses ▪ Growth in Torics and Multifocals New fits ▪ Growing global wearer base Trade-up ▪ Growing prevalence of myopia Geographic expansion ▪ 1/3 of the world’s population is myopic going to 1/
Slide 10: A Global Leader in Myopia Management
A Global Leader in Myopia Management Broadest portfolio of science-based treatment options addressing the progression of myopia in children Ortho-k Only FDA approved Innovative myopia myopia control product management spectacles Broad range of market- leading Ortho-k lenses 10
Slide 11: MiSight 1 day
MiSight® 1 day First and only FDA-approved(1) myopia control contact lens Business Highlights Growth Drivers(3) ▪ Launching Brilliant FuturesTM Myopia ▪ Works for nearly all myopic children Management Program with MiSight® in ▪ Cuts myopia progression by roughly 59% multiple countries worldwide incl
Slide 12: CooperVision: History of success
CooperVision History of success Durable Sales Growth Outpacing Market Growth Annual Sales Market Share CAGR 6.4% $1,973 $2,152 25% $1,882 $1,843 24% 24% $1,577 $1,674 23% 23% 22% FY16 FY17 FY18 FY19 FY20 FY21 CY15 CY16 CY17 CY18 CY19 CY20 Note: Sales $ in millions Source: Management estimates and in
Slide 13: CooperVision revenue by product category and geography
CooperVision Revenue by product category and geography FY21 Revenue $2.15B Revenue by Category Revenue by Geography Non single-use Asia Pacific sphere, other 23% 28% Single- use EMEA sphere Toric 38% 29% 32% Americas 39% Multifocal 11% 13
Slide 14: CooperVision: Well positioned to succeed
CooperVision Well positioned to succeed Products Support Relationships Diverse suite of best-in-class Branded and customized products to fit a wide range of solutions Global footprint patient needs Logistical and 1 Day FRP distribution excellence Sphere Toric Multifocal Strong key account Extended R
Slide 15: CooperSurgical: Healthy women, babies and families
CooperSurgical Healthy women, babies and familiesTM FY21 Revenue $771M Revenue by Category Fertility 41% Office & surgical products 59% 15
Slide 16: CooperSurgical: Fertility portfolio well positioned for success
CooperSurgical Fertility portfolio well positioned for success Business Highlights Fertility Industry Highlights ▪ Broadest medical device coverage of the Medical Devices for the IVF Cycle(1) entire IVF cycle(1) $1.8B+ 5-10% Global Annual ▪ Pioneers in IVF genetic testing (state-of-the- Market1 Grow
Slide 17: CooperSurgical: Extensive office and surgical platform
CooperSurgical Extensive office and surgical platform Business Highlights Industry Highlights ▪ Produce over 600 clinically-relevant medical ▪ Medical Device Drivers: devices used by women’s health care providers – Shifting to minimally invasive procedures Gynecology Obstetrics in gynecology and obs
Slide 18: CooperSurgical: Office and surgical – Paragard IUD
CooperSurgical Office and surgical – Paragard IUD Business Highlights IUD Industry Highlights ▪ Only US FDA-approved 100% Hormone Free Non- Intrauterine Device (IUD) Hormonal 17% ▪ Over 99% effective ~$1.2B ▪ One simple active ingredient – Copper US Market ▪ Lasts up to 10 years with Immediate Hormo
Slide 19: CooperSurgical: History of success
CooperSurgical History of success Annual Sales CAGR 14.6% $771 $651 $680 $588 $465 $390 FY16 FY17 FY18 FY19 FY20 FY21 Note: Sales $ in millions 19
Slide 20: Socially and Environmentally Responsible
Socially and Environmentally Responsible Committed to enhancing the health and wellness of people and communities locally and globally Sustainability Our Employees Giving and Community Involvement 20
Slide 21: Well Positioned for the Future
Well Positioned for the Future Operating in two strong markets Revenue growth exceeding our markets Investing in the infrastructure of the business and new products Positioned to achieve long-term objectives Track record of success 21
The Cooper Companies — Investor Presentation (January 2022) on 6ix